Blurbs

Analysts Are Bullish on These Healthcare Stocks: Cormedix (CRMD), TG Therapeutics (TGTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cormedix (CRMDResearch Report) and TG Therapeutics (TGTXResearch Report) with bullish sentiments.

Cormedix (CRMD)

Needham analyst Serge Belanger maintained a Buy rating on Cormedix today and set a price target of $13.00. The company’s shares closed last Thursday at $3.09, close to its 52-week low of $2.65.

According to TipRanks.com, Belanger has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.2% and a 37.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Phasebio Pharmaceuticals.

Cormedix has an analyst consensus of Strong Buy, with a price target consensus of $14.33, implying a 371.4% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $14.00 price target.

See today’s best-performing stocks on TipRanks >>

TG Therapeutics (TGTX)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics today and set a price target of $17.00. The company’s shares closed last Thursday at $8.57, close to its 52-week low of $3.48.

According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -31.6% and a 20.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TG Therapeutics with a $18.00 average price target, which is a 208.7% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $19.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CRMD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More